YMAB - Y-mAbs Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
32.85
+0.21 (+0.64%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close32.64
Open32.79
Bid0.00 x 800
Ask0.00 x 900
Day's Range32.74 - 33.78
52 Week Range15.17 - 34.49
Volume152,248
Avg. Volume244,230
Market Cap1.3B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.10
Earnings DateNov 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.57
  • GlobeNewswire

    Y-mAbs and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for Omburtamab

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the European Medicines Agency (“EMA”) has agreed to the Company’s proposed Pediatric Investigation Plan (“PIP”) for omburtamab. The decision was made on the basis of a positive opinion from EMA’s Pediatric Committee (“PDCO”).

  • GlobeNewswire

    Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11

    NEW YORK, Dec. 05, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Y-mAbs Initiates Rolling Submission of Biologics License Application to U.S. FDA for Naxitamab for Treatment of Neuroblastoma

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) the first portions of its Biologics License Application (“BLA”) for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma under the FDA’s Rolling Review process. In August 2018, naxitamab, which is an anti-GD2 monoclonal antibody, received Breakthrough Therapy Designation by the FDA, which facilitates frequent interactions with the FDA review team.

  • GlobeNewswire

    Y-mAbs Announces Update on Omburtamab in DSRCT

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a clinical update on omburtamab for Desmoplastic Small Round Cell Tumor (“DSRCT”). Data was presented at the 2019 Connective Tissue Oncology Society (“CTOS”) Annual Meeting in Tokyo, Japan on November 15, 2019, by Dr. Shakeel Modak from Memorial Sloan Kettering Cancer Center (“MSK”) in New York.

  • GlobeNewswire

    Y-mAbs Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

    NEW YORK, Nov. 13, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Y-mAbs to Announce Third Quarter 2019 Financial and Operating Results on November 13

    NEW YORK, Nov. 06, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its third quarter 2019 financial and.

  • GlobeNewswire

    Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its public offering of 5,134,750 shares of its common stock, at a public offering price of $28.00 per share, which includes the exercise in full of the underwriters' option to purchase 669,750 additional shares of common stock. The aggregate gross proceeds to Y-mAbs, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $143.8 million.

  • Benzinga

    Y-mAbs Flags Potential Delay In Pre-BLA Meeting, Sticks To Regulatory Filing Timeline

    Y-mAbs develops novel antibody therapeutics for oncology targets based on technology licensed from Memorial Sloan Kettering Cancer Center. Omburtamab is an antibody that is broadly reactive with human solid tumors.

  • Here’s What Hedge Funds Think About Y-mAbs Therapeutics, Inc. (YMAB)
    Insider Monkey

    Here’s What Hedge Funds Think About Y-mAbs Therapeutics, Inc. (YMAB)

    The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]

  • GlobeNewswire

    Y-mAbs Announces Pricing of Public Offering of Common Stock

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the pricing of its public offering of 4,465,000 shares of its common stock at a public offering price of $28.00 per share. In addition, Y-mAbs has granted the underwriters a 30-day option to purchase up to an additional 669,750 shares of common stock at the public offering price, less the underwriting discounts.

  • GlobeNewswire

    Y-mAbs Announces Proposed Public Offering of Common Stock

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the commencement of a registered underwritten public offering of up to $125 million in shares of its common stock. All shares in the offering are expected to be offered by the Company.

  • Benzinga

    The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive ...

  • We're Not Very Worried About Y-mAbs Therapeutics's (NASDAQ:YMAB) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Y-mAbs Therapeutics's (NASDAQ:YMAB) Cash Burn Rate

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Y-mAbs Announces Positive Omburtamab Clinical Data

    Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a clinical update on omburtamab for the treatment of central nervous system (CNS) leptomeningeal metastases from neuroblastoma and a number of additional cancer indications. Data was presented at the International Society of Pediatric Oncology (SIOP) Annual Congress in Lyon, France on October 26, 2019 by Dr. Kim Kramer from Memorial Sloan Kettering Cancer Center (MSK) in New York.

  • GlobeNewswire

    Y-mAbs Announces Naxitamab Update

    Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update on one of the Company’s lead products, naxitamab for the treatment of neuroblastoma and osteosarcoma, was made at the International Society of Pediatric Oncology (SIOP) Annual Congress held in Lyon, France. Naxitamab is currently being evaluated for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma, osteosarcoma and other GD2-positive tumors.

  • Benzinga

    Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows

    Shares of Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) seem undervalued, given the market opportunities of the company’s core, late stage assets as well as upside potential from its label expansions and earlier-stage ...

  • GlobeNewswire

    Y-mAbs Announces Data to be Presented at 2019 CTOS

    NEW YORK, Aug. 30, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • YmAbs Therapeutics, Inc. (YMAB) Q2 2019 Earnings Call Transcript
    Motley Fool

    YmAbs Therapeutics, Inc. (YMAB) Q2 2019 Earnings Call Transcript

    YMAB earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Y-mAbs Announces Second Quarter 2019 Financial Results and Recent Corporate Developments

    NEW YORK, Aug. 14, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • How Much Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Do Insiders Own?
    Simply Wall St.

    How Much Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Do Insiders Own?

    The big shareholder groups in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have power over the company. Institutions will...

  • GlobeNewswire

    Y-mAbs to Announce Second Quarter 2019 Financial and Operating Results on August 14

    NEW YORK, Aug. 07, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its second quarter 2019 financial and.

  • GlobeNewswire

    Y-mAbs Announces Successful Pre-BLA Meeting with FDA for Naxitamab

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has completed a successful Type B Pre-Biologics License Application (“Pre-BLA”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential pathway for FDA approval of naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma. At the meeting, the Company reached alignment with the FDA on an Accelerated Approval Pathway for naxitamab along with a rolling BLA submission.

  • GlobeNewswire

    Y-mAbs Announces Recruitment Status for Pivotal Trials

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the status of patient recruitment for the Company’s two pivotal phase II trials, one for omburtamab for the treatment of CNS/LM from neuroblastoma and the other for naxitamab for the treatment of relapsed/refractory high-risk neuroblastoma. The Company expects the study to remain open and continue enrolling patients until the product potentially becomes available on the market and believes it remains on target to file a biologic license application (“BLA”) by the end of 2019 under the breakthrough therapy designation (“BTD”) the Company previously received from the FDA.

  • GlobeNewswire

    Y-mAbs Secures Commercial Radiolabeling Capacity

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Company has entered a development, manufacturing and supply agreement with SpectronRx in South Bend, Indiana, to secure access to clinical and commercial scale radiolabeling capacity for omburtamab. The Company expects to file a biologics license application (“BLA”) for omburtamab for the treatment of CNS/LM from neuroblastoma during 2019. The facility will also serve as back-up for the Company’s overseas activities,” stated Thomas Gad, Founder, Chairman, President and Head of Business Development and Strategy.

  • GlobeNewswire

    Y-mAbs Announces Data to be Presented at 2019 SIOP

    NEW YORK, June 26, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.